“…Moreover, mucus production is increased in IBD, requiring nanoparticles that can penetrate and diffuse through the mucus, which is the case for NPL ( Murgia et al, 2018 ). Hence, the NPL combine three potential advantages for drug delivery in the context of IBD: (i) NPL are muco-penetrating nanocarriers, thanks to their size bellow 100 nm (here 65 nm, Table 1 ) and their phospholipid core ( Fasquelle et al, 2020 ); (ii) they quickly interact and penetrate cells, due to their highly cationic surface charge (here +35 mV) ( Le et al, 2018 ); (iii) they were proved to associate and deliver hydrophobic drugs ( Kroubi et al, 2010 ). They can also protect a drug from oxidation, as shown for the anti-parasitic diminazene ( Kroubi et al, 2010 ), which is a particular advantage when using curcumin ( Betbeder et al, 2015 ).…”